Brain Cancer Clinical Trials in Pittsburgh

Showing 61-80 of 181 trials

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Cervical CancerColorectal CancerEsophageal Cancer+16 more

Telix Pharmaceuticals (Innovations) Pty Ltd11 participantsStarted Jun 2023

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +7 more locations

Active Not RecruitingPhase 1/2< 1 mile

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

NCT04019262

This is a prospective, randomized, open-label, exploratory trial of temozolomide-based chemo-radiotherapy which compares two widely used established radiation schedules with either 40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules in patients with glioblastoma.

Glioblastoma

John Flickinger2 participantsStarted Dec 2021

Pittsburgh, Pennsylvania, United States

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma

Brain Cancer Trials in Other Cities

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma

VB-111 in Surgically Accessible Recurrent/Progressive GBM

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Other Conditions in Pittsburgh